Embecta Corp. (EMBC) stock
Close on Nov 11, 2026Market cap $369.99MP/E 4.4Yield 9.19%
Embecta Corp. saw revenue fall 7.6% to $1.02B over the twelve months to Jun 30, 2026. Operating income rose 5.5% to $223.50M, moving the operating margin from 19.2% to 21.9%. Free cash flow was $164.60M, up 24.4% from a year earlier. At the latest close the market valued the company at $369.99M, 4.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $369.99M
- P/E ratio
- 4.4
- Price to sales
- 0.36
- Price to book
- –
- Dividend yield
- 9.19%
- Free cash flow yield
- 44.49%
Fundamentals
- Revenue
- $1.02B
- Net income
- $87.50M
- EPS, diluted
- $1.47
- Free cash flow
- $164.60M
- Book value per share
- -$10.47
- Diluted shares
- 59M
Trading
- Next earnings
- Nov 24, 2026 (estimated, before the open)
- Previous close
- $6.43
- Open
- $6.41
- Day's range
- $6.35 – $6.59
- Volume
- 721,018
- Average volume (20 days)
- 819,758
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000 (since May 2022)
- Beta (5 years)
- 0.68
- 52-week range
- $2.77 – $14.91
- RSI (14 days)
- 56.9
- Volatility (1 year)
- 81.9%
- Relative volume
- 0.58×
- WACC
- 5.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EMBC | S&P 500 | Difference | EMBC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.9% | -2.4% | +17.3 pts | ||
| 3 months | +34.1% | -1.2% | +35.2 pts | ||
| Year to date | -44.0% | +12.3% | −56.2 pts | ||
| 1 year | -52.6% | +12.4% | −65.0 pts | ||
| 3 years | -50.5% | +78.8% | −129.3 pts | -20.9% | +21.4% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Embecta filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
About Embecta
Surgical & Medical Instruments & Apparatus
Embecta Corp. is a medical device manufacturer that focuses on diabetes management solutions. The company produces conventional and safety pen needles, insulin syringes, and safety injection devices designed for insulin and diabetes medication administration. These products feature protective mechanisms, such as automatic shields and sliding arms, to reduce accidental needlestick injuries for users and clinical personnel. Embecta supplies its diabetes injection devices to individual patients managing diabetes, healthcare professionals, hospitals, retail pharmacies, and other institutional healthcare networks.
Company profile, executives and historyEmbecta stock: common questions
What is Embecta's stock price?
EMBC closed at $6.53 on Nov 11, 2026, up 1.56% on the day. Over the past 52 weeks it traded between $2.77 and $14.91.
What is Embecta's market cap?
Embecta was worth $369.99M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EMBC's P/E ratio?
EMBC trades at 4.4 times earnings, based on diluted earnings per share of $1.47 over the twelve months to Jun 30, 2026.
How much revenue does Embecta make?
Embecta reported revenue of $1.02B for the twelve months to Jun 30, 2026, down 7.6% from a year earlier.
Does Embecta pay a dividend?
Yes. Embecta paid $0.60 per share over the last twelve months, a yield of 9.19% at the latest price.
When does Embecta report earnings next?
Embecta is expected to report Q4 FY2026 results on Nov 24, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has EMBC stock performed over the past year?
Including dividends, EMBC returned -52.6% over the past year, against +12.4% for the S&P 500.
How many EMBC shares are sold short?
6M shares were sold short at the latest FINRA report, 10.68% of the float, or 6.8 days of average trading volume.
Who are Embecta's competitors?
Companies most similar to Embecta by business, industry and size include TNDM, MMED, PODD, STVN, TFX.
See a number that looks wrong?